Mydecine.png
Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th
23 juin 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, June 23, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
Mydecine.png
Mydecine Unveils Artificial Intelligence Drug Discovery Program
16 juin 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, June 16, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
Mydecine.png
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
08 juin 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, June 08, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine.png
Mydecine to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference on June 17th
03 juin 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, June 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine.png
Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
25 mai 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, May 25, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
Mydecine.png
Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets
19 mai 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, May 19, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed...
Mydecine.png
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update
18 mai 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, May 18, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine.png
Mydecine to Participate in the Benzinga Global Small Cap Conference on May 13th
10 mai 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, May 10, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine.png
Mydecine Announces Partnership with LeadGen Labs
05 mai 2021 07h30 HE | Mydecine Innovations Group Inc.
DENVER, May 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine.png
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
03 mai 2021 07h30 HE | Mydecine Innovations Group Inc.
Positioned as Leader in Emerging Psychedelic Therapeutics Market through Robust IP Portfolio, Novel Clinical Trials and Evolving Proprietary TechnologyStrengthened Balance Sheet with Approximately $30...